<DOC>
	<DOCNO>NCT02636244</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety SHAPE Gel apply topically adult patient alopecia areata scalp .</brief_summary>
	<brief_title>Safety Efficacy Study SHAPE Gel Alopecia Areata</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Diagnosis scalp alopecia areata scalp hair loss due alopecia areata minimum six month maximum two year . Patients take thyroid medication hormonal therapy must stable dose 6 month maintain throughout study . Willingness maintain hair style , include shampoo hair dye , throughout study period . Willingness small micro dot tattoo place allow photographic analysis treatment application study medication . History systemic cutaneous malignancy and/or lymphoproliferative disease , patient : 3 basal cell carcinoma ; three well differentiate cutaneous squamous cell carcinoma ; and/or cervical intraepithelial neoplasm ( CIN ) , treat successfully evidence disease , treat great 6 month prior study entry . Current actinic keratosis scalp and/or face Nevi cutaneous lesion think suspicious malignancy . History current gastrointestinal , pulmonary , cardiovascular , genitourinary hematological disease , CNS disorder , infectious disease coagulation disorder would preclude participation completion study assessment . Positive hepatitis B surface antigen , HIV hepatitis C. Coexistent androgenetic alopecia : male : NorwoodHamilton stage IV , V VI ; female : Ludwig stage II III . Unwillingness discontinue use nonbreathable wig , weave shave scalp throughout course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>